Evidence map›Paper›PMID 40619750›Full record

SynthesisFuture microbiology2025

Prevalence of colistin resistance in clinical

Negar Narimisa, Shirin Bavari, Forough Goodarzi, Amin Khoshbayan

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Carbapenem and colistin-resistantJAC-antimicrobial resistance · 2026
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Negar NarimisaDepartment of Microbiology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Shirin BavariDepartment of Microbiology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Forough GoodarziDepartment of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Amin KhoshbayanDepartment of Microbiology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective

methodsWe conducted a systematic literature review of relevant studies available in the PubMed, Scopus, and Web of Science databases up to December 2023. Following this, a meta-analysis was performed using Stata software to determine the overall prevalence of colistin resistance in

resultsThis meta-analysis reviewed 682 studies and found a global prevalence of colistin resistance at 13% among all

conclusionThis study presents evidence of a substantial global prevalence of colistin resistance among clinical isolates of

Indexed as

Anti-Bacterial AgentsColistinDrug Resistance, BacterialKlebsiella InfectionsKlebsiella pneumoniaeCross InfectionHumansMicrobial Sensitivity TestsPrevalenceAnti-Bacterial AgentsColistinantibiotic resistancecolistinKlebsiella pneumoniaemeta analysispublic health

Identifiers

PMID40619750
PMCPMC12320877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.